scispace - formally typeset
X

Xian Wang

Researcher at Sir Run Run Shaw Hospital

Publications -  113
Citations -  11684

Xian Wang is an academic researcher from Sir Run Run Shaw Hospital. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 37, co-authored 104 publications receiving 9926 citations. Previous affiliations of Xian Wang include The Chinese University of Hong Kong & Zhejiang University.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment

TL;DR: Understanding the novel function of autophagy may allow us to develop a promising therapeutic strategy to enhance the effects of chemotherapy and improve clinical outcomes in the treatment of cancer patients.
Journal ArticleDOI

N6-methyladenosine links RNA metabolism to cancer progression.

TL;DR: The regulation and function of m6A in human carcinogenesis is summarized in this review, finding that it is contributing to the self-renewal of cancer stem cell, promotion of cancer cell proliferation, and resistance to radiotherapy or chemotherapy.
Journal ArticleDOI

MicroRNAs as potential biomarkers in cancer: opportunities and challenges.

TL;DR: In this review, the current understanding of miRNAs as potential biomarkers in human cancers is summarized.
Journal ArticleDOI

EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells

TL;DR: Autophagy inhibition represents a promising approach to improve the efficacy of EGFR-TKIs in the treatment of patients with advanced non-small-cell lung cancer.